HK1082762A1 - Antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis - Google Patents

Antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis

Info

Publication number
HK1082762A1
HK1082762A1 HK06100885.2A HK06100885A HK1082762A1 HK 1082762 A1 HK1082762 A1 HK 1082762A1 HK 06100885 A HK06100885 A HK 06100885A HK 1082762 A1 HK1082762 A1 HK 1082762A1
Authority
HK
Hong Kong
Prior art keywords
methods
polynucleotides encoding
inhibiting angiogenesis
encoding same
antiangiogenic peptides
Prior art date
Application number
HK06100885.2A
Other languages
English (en)
Inventor
Donald J Davidson
Jieyi Wang
Earl J Gubbins
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority claimed from HK99104850A external-priority patent/HK1021191A1/xx
Publication of HK1082762A1 publication Critical patent/HK1082762A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06100885.2A 1996-05-03 1999-10-27 Antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis HK1082762A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/643,219 US5801146A (en) 1996-05-03 1996-05-03 Compound and method for inhibiting angiogenesis
US08/832,087 US5981484A (en) 1996-05-03 1997-04-03 Antiangiogenic peptides and methods for inhibiting angiogenesis
HK99104850A HK1021191A1 (en) 1996-05-03 1999-10-27 Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
HK1082762A1 true HK1082762A1 (en) 2006-06-16

Family

ID=24579877

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100885.2A HK1082762A1 (en) 1996-05-03 1999-10-27 Antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis

Country Status (8)

Country Link
US (2) US5801146A (cs)
JP (1) JP4722989B2 (cs)
AT (1) ATE513908T1 (cs)
CA (1) CA2253243C (cs)
CZ (1) CZ300141B6 (cs)
ES (1) ES2367307T3 (cs)
HK (1) HK1082762A1 (cs)
IL (2) IL126626A (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20020031518A1 (en) * 1996-10-09 2002-03-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Plasminogen fragment having activity to inhibit tumor metastasis and growth and process for preparing same technical field
CA2318578A1 (en) * 1998-01-20 1999-07-22 Abbott Laboratories Specific antibodies to kringle 5 of apoliprotein a and methods of use therefor
JP2002520367A (ja) * 1998-07-14 2002-07-09 ブリストル−マイヤーズ スクイブ カンパニー アンギオスタチンのリジン結合フラグメント
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6465424B1 (en) 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
BR0010750A (pt) * 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US6576610B1 (en) 1999-10-04 2003-06-10 Nuvas, Llc Use of a context-dependent functional entity to enhance the efficacy of an agent
JP2003517007A (ja) * 1999-12-15 2003-05-20 エントレメッド インコーポレイテッド 内皮細胞増殖阻害組成物および方法
EP1246642B1 (fr) * 1999-12-30 2005-09-07 Aventis Pharma S.A. Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
DK1299727T3 (da) 2000-07-12 2009-06-15 Agensys Inc Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
US20020159992A1 (en) * 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
US20030054988A1 (en) * 2000-11-02 2003-03-20 Weidong-Richard Ji Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
US20040121945A1 (en) * 2000-12-15 2004-06-24 Hong Liang Compositions and methods for inhibiting endothelial cell proliferation
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20030211519A1 (en) * 2001-12-19 2003-11-13 Davidson Donald J. Uses of an endothelial cell receptor
US6818420B2 (en) * 2002-02-27 2004-11-16 Biosource International, Inc. Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
US7285277B2 (en) * 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
US20040121955A1 (en) * 2002-04-01 2004-06-24 Mulligan-Kehoe Mary Jo Methods for modulating angiogenesis
US20050053993A1 (en) * 2002-12-18 2005-03-10 Davidson Donald J. Uses of an endothelial cell receptor
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20080287384A1 (en) * 2005-09-19 2008-11-20 Marsha Rosner Methods of Identifying Agents Having Antiangiogenic Activity
TWI513799B (zh) * 2005-11-09 2015-12-21 Entegris Inc 用於回收具有低ｋ介電材料之半導體晶圓的組成物及方法
US8933031B2 (en) * 2008-02-04 2015-01-13 Shanghai First People's Hospital Polypeptide inhibiting angiogenesis and application thereof
MX2012000475A (es) * 2009-07-10 2012-03-26 Thrombogenics Nv Variantes de plasminogeno y plasmina.
CN101974505A (zh) * 2010-09-30 2011-02-16 西北大学 一种表达高活性可溶型血管生长抑制剂Kringle5三聚体工程菌的高密度发酵方法及其相应蛋白的分离纯化方法
EP4190911A4 (en) * 2020-08-20 2024-03-13 Talengen Int Ltd METHOD AND DRUGS FOR TUMOR TREATMENT

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US5469431A (en) * 1993-07-12 1995-11-21 Philips Electronics North America Corp. Method of and apparatus for channel mapping with relative service identification
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CN1309833C (zh) * 1994-04-26 2007-04-11 儿童医学中心公司 血管生成抑制素及其在制备药物中的用途
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
DE69631972T2 (de) * 1995-12-13 2005-01-05 The Children's Medical Center Corp., Boston Proliferationsinhibitor von endothellzellen und dessen verwendung

Also Published As

Publication number Publication date
US5981484A (en) 1999-11-09
CA2253243A1 (en) 1997-11-13
IL195827A0 (en) 2011-08-01
ES2367307T3 (es) 2011-11-02
CA2253243C (en) 2010-04-06
ATE513908T1 (de) 2011-07-15
JP2009106290A (ja) 2009-05-21
IL195827A (en) 2014-03-31
IL126626A (en) 2009-12-24
CZ300141B6 (cs) 2009-02-18
US5801146A (en) 1998-09-01
JP4722989B2 (ja) 2011-07-13

Similar Documents

Publication Publication Date Title
HK1082762A1 (en) Antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
EP1612272A3 (en) Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
BG101131A (en) 2-oxo-and 2-thio-1,2-dihydroquinolinyl-oxazolidinons
NZ333588A (en) Sulphamates as anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
HK1023566A1 (en) Process to prepare tolterodine
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
BG102589A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists
GB9525692D0 (en) Appliance for treating garments
PL304861A1 (en) Butadiene-1,3 hydroformylation process
ZA952344B (en) Novel protease for treating devitalized tissue
HK1050012A1 (en) Peptides having antiangiogenic activity
BG103649A (en) Method for the preparation of eprosartan
AU8229887A (en) Process for producing pig iron
BG103650A (en) Method for the preparation of eprosartan
IL128028A0 (en) Treatment of psychotic disorders
ZA976927B (en) Process for making pig iron.
GB2352518B (en) Screening of compunds for therapeutic activity
TW239124B (en) Process for the preparation of 2,4,5-tribromopyrrole-3-carbonitrile
IL135516A0 (en) Process for n-desmethylating erythromycins and derivatives thereof
AU2308397A (en) Steam iron
HU9600379D0 (en) Cosmetic composition, especially for treating of acne
NZ328739A (en) Treatment of estrogen therapy using 8,9-dehydroesterone
GR1002949B (el) Φαρμακα
HUP9802226A3 (en) 1,6-disubstituted isochromans for treatment of migraine headaches

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150505